




Searching News Database: SciClone Pharmaceuticals
HSMN NewsFeed - 8 Jun 2017
SciClone Enters Into Definitive Merger Agreement To Be Acquired By Consortium Led By GL Capital
SciClone Enters Into Definitive Merger Agreement To Be Acquired By Consortium Led By GL Capital
HSMN NewsFeed - 22 Sep 2015
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
HSMN NewsFeed - 10 Feb 2014
SciClone Appoints Charles Meng as General Counsel and Vice President of Compliance
SciClone Appoints Charles Meng as General Counsel and Vice President of Compliance
HSMN NewsFeed - 20 Aug 2009
VistaGen Appoints Industry Veteran Shawn Singh as Chief Executive Officer
VistaGen Appoints Industry Veteran Shawn Singh as Chief Executive Officer
HSMN NewsFeed - 7 Aug 2008
SciClone Pharmaceuticals Appoints Jeffery Lange as Vice President, Business Development
SciClone Pharmaceuticals Appoints Jeffery Lange as Vice President, Business Development
HSMN NewsFeed - 11 Feb 2008
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
HSMN NewsFeed - 20 Dec 2007
Cytori Appoints Richard J. Hawkins, Senior Life Science Executive, to Board of Directors
Cytori Appoints Richard J. Hawkins, Senior Life Science Executive, to Board of Directors
HSMN NewsFeed - 26 Apr 2007
Avantogen Oncology, Inc. Completes Major Transaction With SciClone Pharmaceuticals, Inc.
Avantogen Oncology, Inc. Completes Major Transaction With SciClone Pharmaceuticals, Inc.
HSMN NewsFeed - 28 Dec 2006
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
HSMN NewsFeed - 22 Dec 2006
SciClone and Sigma-Tau Announce Positive Interim Survival Data From Large Phase 2 Malignant Melanoma Trial
SciClone and Sigma-Tau Announce Positive Interim Survival Data From Large Phase 2 Malignant Melanoma Trial
HSMN NewsFeed - 25 May 2006
SciClone Reports Final Results From Second ZADAXIN U.S. Phase 3 Hepatitis C Trial
SciClone Reports Final Results From Second ZADAXIN U.S. Phase 3 Hepatitis C Trial
Additional items found! 26

Members Archive contains
26 additional stories matching:
SciClone Pharmaceuticals
(Password required)
SciClone Pharmaceuticals
(Password required)